Wilmington Savings Fund Society FSB Sells 628 Shares of Teleflex Incorporated (NYSE:TFX)

Wilmington Savings Fund Society FSB cut its stake in Teleflex Incorporated (NYSE:TFX) by 2.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,131 shares of the medical technology company’s stock after selling 628 shares during the quarter. Wilmington Savings Fund Society FSB owned 0.06% of Teleflex worth $4,829,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of TFX. Janus Henderson Group PLC boosted its position in shares of Teleflex by 2.8% during the third quarter. Janus Henderson Group PLC now owns 5,376,452 shares of the medical technology company’s stock worth $1,329,704,000 after purchasing an additional 147,147 shares in the last quarter. State Street Corp lifted its holdings in Teleflex by 1.0% during the third quarter. State Street Corp now owns 2,057,080 shares of the medical technology company’s stock worth $508,757,000 after acquiring an additional 21,291 shares in the last quarter. Geode Capital Management LLC grew its stake in Teleflex by 0.5% in the third quarter. Geode Capital Management LLC now owns 1,130,560 shares of the medical technology company’s stock valued at $278,676,000 after acquiring an additional 5,746 shares during the period. Massachusetts Financial Services Co. MA raised its position in shares of Teleflex by 0.4% during the third quarter. Massachusetts Financial Services Co. MA now owns 427,579 shares of the medical technology company’s stock worth $105,749,000 after purchasing an additional 1,884 shares during the period. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Teleflex by 31.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 407,442 shares of the medical technology company’s stock valued at $100,768,000 after purchasing an additional 96,958 shares in the last quarter. 95.62% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TFX has been the topic of several research analyst reports. Mizuho dropped their target price on shares of Teleflex from $275.00 to $250.00 and set a “neutral” rating on the stock in a report on Friday, November 1st. Royal Bank of Canada dropped their price objective on shares of Teleflex from $275.00 to $245.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of Teleflex in a research note on Monday, December 16th. Truist Financial lowered their target price on Teleflex from $227.00 to $200.00 and set a “hold” rating for the company in a report on Wednesday, December 18th. Finally, StockNews.com upgraded Teleflex from a “hold” rating to a “buy” rating in a report on Thursday, November 28th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Teleflex has an average rating of “Moderate Buy” and an average target price of $252.50.

Teleflex Trading Down 1.4 %

Shares of Teleflex stock opened at $171.13 on Friday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.39 and a current ratio of 2.42. The firm has a 50-day moving average of $180.04 and a 200-day moving average of $211.25. Teleflex Incorporated has a 52-week low of $170.30 and a 52-week high of $256.85. The stock has a market cap of $7.95 billion, a PE ratio of 34.02, a PEG ratio of 1.72 and a beta of 1.16.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.